Straight from the Desk
Syz the moment
Live feeds, charts, breaking stories, all day long.
- All
- us
- equities
- Food for Thoughts
- macro
- Bonds
- Central banks
- Asia
- sp500
- technical analysis
- investing
- bitcoin
- markets
- inflation
- interest-rates
- europe
- Crypto
- Commodities
- ETF
- AI
- nvidia
- tech
- Forex
- earnings
- gold
- performance
- Real Estate
- oil
- bank
- geopolitics
- apple
- nasdaq
- Alternatives
- Volatility
- energy
- magnificent-7
- switzerland
- emerging-markets
- sentiment
- tesla
- trading
- ESG
- Money Market
- Middle East
- UK
- assetmanagement
- bankruptcy
- meta
- russia
- France
- Turkey
- amazon
- ethereum
- Industrial-production
- microsoft
- africa
- Healthcare
- Market Outlook
- brics
Nvidia establishes itself in the $1 trillion club. But expectations for Wednesday's numbers are immense
In Q1, Nvidia $NVDA crushed analysts’ revenue estimates by 10.4% as revenues rose 19% QoQ to $7.19 billion. The strong sequential growth was led by record data center revenue, primarily helped by accelerated computing as generative AI drove high demand for Nvidia’s products. For Q2, Nvidia is projecting revenues of $11B, up 68% QoQ, with a 400 bp increase in gross margins as AI takes center stage. The AI-hype has driven some stocks valuations to extreme levels. Nvidia is the most emblematic one among large-caps is with a P/E ratio which went from under 50x to 224x in just 8 months. Source: Bloomberg
Think you're bad at timing the market? CEOs Business Confidence historically hits the lowest level at market bottoms...
Sounds like an effective contrarian indicator... Source: Brian Feroldi
Investors learn the most by studying other investors' mistakes
Source: Brian Feroldi
Higher real bond yields create a challenge for global equities valuations
Source: Bloomberg
"The real money in investment will be made not out of buying and selling but of owning and holding securities" - Charlie Munger
Source: Investment Books (Dhaval)
Eli Lilly stock hit a new record high yesterday as the company continues to record a surge in sales for its buzzy diabetes drug Mounjaro
Sales of Mounjaro, which has also gained popularity for weight loss, came in at $979.7 million for the second quarter, up from $16 million a year earlier when it was introduced (2Q results were publichsed 2 weeks ago). That helped the drug company post higher-than-expected sales for the second quarter. Novo Nordisk is also surfing on the strong demand for a similar weight loss blockbuster
Investing with intelligence
Our latest research, commentary and market outlooks